高危转移性激素初治前列腺癌患者的临床结局:J-ROCK观察性研究的3年中期分析
J-ROCK登记研究纳入日本974例高危转移性激素初治前列腺癌患者,分为队列1(ADT或CAB,38.1%)和队列2(ADT联合ARSI或多西他赛,61.9%)。队列2的PFS(校正HR 0.42)、至CRPC时间(0.28)和OS(0.54)均优于队列1,队列2特殊关注不良反应发生率15.1%高于队列1的1.3%。
要点
- 队列2(ADT联合ARSI或多西他赛)的PFS、至CRPC时间和OS均长于队列1(ADT或CAB)。
- 队列2特殊关注不良反应发生率为15.1%,高于队列1的1.3%,但安全性被认为可耐受。
- 队列1中CAB占67.4%,队列2中阿比特龙联合泼尼松龙使用最多(59.4%)。
核心结论
- ADT联合ARSI或多西他赛在高危mHNPC中的使用频率高于标准ADT/CAB,且与更有利的临床结局相关。
- 尽管队列2的特殊关注不良反应报告更多,但安全性特征被认为可耐受。
研究设计与样本
- 纵向、多中心J-ROCK登记研究,纳入2019年5月后在日本开始ADT的患者,分为队列1(ADT或CAB)和队列2(ADT联合ARSI或多西他赛)。
- 共纳入974例患者(队列1:38.1%,队列2:61.9%)。
主要发现
- 队列1中CAB较ADT单药更常用(67.4%),队列2中阿比特龙联合泼尼松龙使用最频繁(59.4%)。
- PSA下降≥50%/≥90%或达到PSA≤0.2/≤0.1 ng/ml的患者比例在队列2倾向于更高。
- 队列2的PFS更长(校正HR 0.42;95%CI 0.31-0.55)。
- 队列2的至CRPC时间更长(HR 0.28;95%CI 0.23-0.36)。
- 队列2的OS更长(HR 0.54;95%CI 0.35-0.82)。
局限性
- 非随机设计。
- ARSI上市许可后的时间长短不一。
- 安全性评估有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen deprivation therapy (ADT), administered alone, as combined androgen blockade (CAB) or as ADT plus androgen receptor signalling inhibitors (ARSIs) or ADT plus docetaxel, is the standard treatment for metastatic hormone-naïve prostate cancer (mHNPC) in Japanese real-world practice. OBJECTIVE: To investigate treatment patterns and clinical outcomes in LATITUDE criteria high-risk mHNPC. DESIGN, SETTING, AND PARTICIPANTS: The longitudinal, multicentre, J-ROCK registry study enrolled patients initiating ADT in Japan after May 2019, and categorised them as cohort 1 (ADT or CAB) or cohort 2 (ADT plus ARSIs or docetaxel). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate-specific antigen (PSA) response, progression-free survival (PFS), time to castrate-resistant prostate cancer (CRPC), overall survival (OS), and safety were evaluated. PFS, time to CRPC, and OS were estimated via the Kaplan-Meier method and between-cohort comparisons via multivariate Cox regression models. RESULTS AND LIMITATIONS: In total, 974 patients were included (cohort 1: 38.1%, cohort 2: 61.9%). CAB was preferred (67.4%) to ADT alone in cohort 1, and abiraterone acetate plus prednisolone was used most frequently in cohort 2 (59.4%). The proportion of patients with ≥50%/≥90% PSA decline or who achieved PSA ≤0.2/≤0.1 ng/ml tended to be higher in cohort 2. PFS (adjusted hazard ratio 0.42; 95% confidence interval [CI] 0.31-0.55), time to CRPC (0.28; 95% CI 0.23-0.36), and OS (0.54; 95% CI 0.35-0.82) were longer in cohort 2. In cohorts 1 and 2, adverse drug reactions of special interest (ADRSIs) occurred in 1.3% and 15.1%, and fatal adverse events occurred in 1.9% and 1.7%, respectively. Limitations included nonrandomised design, varying time since marketing authorisation for ARSIs, and limited safety assessments. CONCLUSIONS: ADT plus ARSIs or docetaxel was used more frequently to treat high-risk mHNPC than standard ADT/CAB and was associated with more favourable clinical outcomes. Although ADRSIs were reported more in cohort 2, the safety profile was considered tolerable. PATIENT SUMMARY: Although many treatment options are available for high-risk metastatic prostate cancer, there are limited reports on real-world clinical experience with different therapies outside of the clinical trial setting. In this study, we compared clinical and safety outcomes with different treatment regimens, using a large series of patients with high-risk metastatic hormone-naïve prostate cancer across Japan. We found that androgen deprivation therapy in combination with newer androgen receptor signalling inhibitors resulted in improved response compared with androgen deprivation therapy alone or in combination with a first-generation antiandrogen.
引用
- Miyake H, Matsumoto R, Fujimoto K, et al. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study. Eur Urol Oncol. 2024. PMID: 38296736. doi:10.1016/j.euo.2023.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。